EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sesen Bio's enterprise value is €-48.38 Mil.
Sesen Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was €40.40 Mil. Therefore, Sesen Bio's EV-to-Revenue for today is -1.20.
The historical rank and industry rank for Sesen Bio's EV-to-Revenue or its related term are showing as below:
STU:PCBK's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.12 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-23), Sesen Bio's stock price is €10.598.
Sesen Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €4.02. Therefore, Sesen Bio's PS Ratio for today is 2.64.
Sesen Bio EV-to-Revenue Historical Data
The historical data trend for Sesen Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sesen Bio's EV-to-Revenue
For the Biotechnology subindustry, Sesen Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sesen Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sesen Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Sesen Bio's EV-to-Revenue falls into.
Sesen Bio's current Enterprise Value is €-48.38 Mil.
Sesen Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sesen Bio's share price for today is €10.598.
Sesen Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sesen Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Sesen Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:PCBK has been successfully added to your 